Albumin-conjugated nanocarriers of Paclitaxel have improved the efficacy of the first-line pancreatic cancer drug Gemcitabine by inhibiting the tumor stroma and suppressing the expression of the gemcitabine-inactivating enzyme cytidine deaminase (56). The gene discussed is CDA; the disease is familial pancreatic carcinoma.